2025 India Anti-Asthma Drugs Market Revenue Opportunities Report
Description
The 2025 India Anti-Asthma Drugs Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Asthma Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Anti-Asthma Drugs Market in India are GSK, Sun Pharmaceutical, Cipla, and Dr. Reddy’s Laboratories. GSK (GlaxoSmithKline), a London-based pharma giant, has a significant presence in India with a focus on respiratory and immunology drugs, including innovative treatments for severe asthma such as depemokimab. Sun Pharmaceutical is India’s largest pharmaceutical company by revenue, offering a wide range of respiratory and anti-asthma medications while holding a considerable share in the Indian pharma sector. Cipla is another key player known for its strong respiratory portfolio and generic drugs supply, especially inhalers and corticosteroids used in asthma management. Dr. Reddy’s Laboratories also contributes heavily with anti-asthma drug formulations and has a notable presence in both domestic and international respiratory markets.
These companies leverage India's growing pharma market driven by high pollution levels and increasing asthma prevalence, leading to strong double-digit growth in anti-asthma drug sales. They focus on both generic and innovative biologic treatments, addressing different severities of asthma, and expanding access with devices like inhalers. In particular, GSK and Sun Pharma emphasize new biologics and combination inhalers, while Cipla and Dr. Reddy’s reinforce affordability and availability in emerging markets including India. These firms are shaping the anti-asthma therapy landscape in India through research, local manufacturing, and distribution networks aligned with rising domestic demand.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Asthma Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Anti-Asthma Drugs Market in India are GSK, Sun Pharmaceutical, Cipla, and Dr. Reddy’s Laboratories. GSK (GlaxoSmithKline), a London-based pharma giant, has a significant presence in India with a focus on respiratory and immunology drugs, including innovative treatments for severe asthma such as depemokimab. Sun Pharmaceutical is India’s largest pharmaceutical company by revenue, offering a wide range of respiratory and anti-asthma medications while holding a considerable share in the Indian pharma sector. Cipla is another key player known for its strong respiratory portfolio and generic drugs supply, especially inhalers and corticosteroids used in asthma management. Dr. Reddy’s Laboratories also contributes heavily with anti-asthma drug formulations and has a notable presence in both domestic and international respiratory markets.
These companies leverage India's growing pharma market driven by high pollution levels and increasing asthma prevalence, leading to strong double-digit growth in anti-asthma drug sales. They focus on both generic and innovative biologic treatments, addressing different severities of asthma, and expanding access with devices like inhalers. In particular, GSK and Sun Pharma emphasize new biologics and combination inhalers, while Cipla and Dr. Reddy’s reinforce affordability and availability in emerging markets including India. These firms are shaping the anti-asthma therapy landscape in India through research, local manufacturing, and distribution networks aligned with rising domestic demand.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
